LaMond Stephen J 4
4 · Peak Bio, Inc. · Filed Nov 3, 2022
Insider Transaction Report
Form 4
Peak Bio, Inc.PKBO
LaMond Stephen J
DirectorSee Remarks
Transactions
- Award
Stock Option (Right to Buy)
2022-11-01+65,265→ 65,265 totalExercise: $8.05From: 2024-01-26Exp: 2029-01-26→ Common Stock (65,265 underlying)
Footnotes (1)
- [F1]Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea ("Legacy Peak Bio"), and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on January 26, 2022. The stock options become fully vested and exercisable after two years from the initial date of grant, subject to the Reporting Person's continued employment with the Issuer.